Result for Q3 2025 The BANK of Greenland’s profit before tax amounts to DKK 132.5 million for the first nine months of 2025, compared to DKK 193.6 million for the same period of 2024. The profit before tax gives a return of 12.1% p.a. on opening equity after disbursement of dividend. The profit before value adjustments and write-downs amounted to DKK 133.4 million compared to DKK 186.2 million for the previous year. Net interest and fee income decreased by DKK 36.0 million to DKK 319.9 million compared to the same period in 2024.  At the end of September 2025, total costs including write-offs amounted to DKK 191.4 million, compared to DKK 173.8 million for the same period of 2024. At the end of September 2025, value adjustments show a capital gain of DKK 13.6 million, compared to a capital gain of DKK 22.6 million for the same period of...

ISTANBUL, , Nov. 05, 2025 (GLOBE NEWSWIRE) — D-MARKET Electronic Services & Trading (d/b/a “Hepsiburada”) (NASDAQ: HEPS), a leading Turkish e-commerce platform (referred to herein as “Hepsiburada” or the “Company”), today announces its unaudited financial results for the third quarter and the nine months ended September 30, 2025. Restatement of financial information: Pursuant to the International Accounting Standard 29, Financial Reporting in Hyperinflationary Economies (“IAS 29”), the financial statements of entities whose functional currency is that of a hyperinflationary economy must be adjusted for the effects of changes in a general price index. Turkish companies reporting under International Financial Reporting Standards (“IFRS”), including the Company, have been required to apply IAS 29 to their financial statements...

CHICAGO, Nov. 05, 2025 (GLOBE NEWSWIRE) — GCM Grosvenor (Nasdaq: GCMG), a global alternative asset management solutions provider, today reported its results for the third quarter 2025. GCM Grosvenor issued a detailed presentation of its results to the Public Shareholders section of GCM Grosvenor’s website at https://www.gcmgrosvenor.com/shareholder-events. The firm’s Board of Directors also approved a $0.12 per share dividend payable on December 15, 2025 to shareholders on record December 1, 2025. Conference Call A conference call to discuss GCM Grosvenor’s financial results will be held today, Wednesday, November 5, 2025, at 10:00 a.m. ET. The call will be accessible via public webcast from the Public Shareholders section of GCM Grosvenor’s website at https://www.gcmgrosvenor.com/shareholder-events, and a replay of the live broadcast...

MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November 19, 2025 ROCKVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its preliminary results for the third quarter ended September 30, 2025 and reiterated its 2025 revenue guidance. Preliminary Third Quarter Results and Recent HighlightsCore business revenue of $6.4 million in the third quarter of 2025. Strategic Platform License SPL Program-related revenue of $0.4 million in the third quarter of 2025. Total revenue...

Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of overall survival (OS) and progression-free survival (PFS) are expected in late Q1 2026. A new response in a third indication has been observed in the fifth and final dosing cohort of the Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody); no dose-limiting toxicities have been observed at any dose level and full topline data are now expected to be presented at a medical meeting in H1 2026. Based on previously reported responses in the CTX-8371 Phase 1 study, cohort expansions in patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC), are expected to begin in Q4 2025. CTX-10726...

HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) — Plains All American Pipeline, L.P. (Nasdaq: PAA) and Plains GP Holdings (Nasdaq: PAGP) today reported third-quarter 2025 results and provided the following highlights and recent developments: Third-Quarter Results and HighlightsReported net income attributable to PAA of $441 million and net cash provided by operating activities of $817 million. Delivered solid Adjusted EBITDA attributable to PAA of $669 million. Exited the quarter with 3.3x leverage ratio, toward the low-end of our target range of 3.25x – 3.75x. In September, Plains successfully raised $1.25 billion in aggregate senior unsecured notes with proceeds allocated toward redeeming senior notes maturing in October 2025 and to partially fund recently announced acquisitions.Recent DevelopmentsOn October 31st, Plains...

BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2025 ending September 30, 2025. Business Updates  On October 23, 2025, the Company received $80 million in gross proceeds in a private placement, before deducting fees and other expenses. The financing includes an initial upfront funding of $80 million and up to an additional $80 million in gross proceeds if all Tranche A warrants are exercised, subject to the terms and conditions specified therein. Additional proceeds of $40 million may be received if all Tranche B warrants are exercised by cash payment upon the achievement of...

TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX:STCK; TSX:STCK.WT.A; TSX:STCK.WT.B) today announced its financial results for the quarter ended September 30, 2025. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. Financial SummaryBook Value per Share (“BVpS”) was $14.26 as at September 30, 2025, compared to $14.34 at June 30, 2025. Total Book Value stood at $188.7 million. During the quarter, the Company successfully raised $35 million through a private placement, further strengthening its capital position as it actively pursues opportunities across late-stage, high-growth private companies.Portfolio Company Highlights SpaceXValuation increased from US$350B to US$400B during the quarter. Successfully completed its 11th Starship test...

FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved comparability report between LX2006 HEK and Sf9 manufacturing processes in November 2025, endorsing use of Sf9 final commercial manufacturing process to begin dosing patients in upcoming pivotal study LX2006 interim clinical data show clinically meaningful improvements across cardiac and neurologic measures of Friedreich ataxia, including left ventricular mass index and the modified Friedreich Ataxia Rating Scale Completed enrollment of LX2020 HEROIC-PKP2 Phase I/II trial with ten participants dosed; interim data from low-dose cohort reported and additional clinical data from high-dose cohorts on track for January 2026 $154 million equity...

ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week 2025 Biologics License Application (BLA) submission through the Accelerated Approval Program for atacicept for the treatment of IgAN to U.S. FDA expected in Q4; potential U.S. commercial launch of atacicept in 2026 Actively enrolling patients in the PIONEER, atacicept monthly dose range finding, and ORIGIN Extend studiesBRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and...